A French update on the Self-Efficacy Measure for Sleep Apnea (SEMSA) to assess continuous positive airway pressure (CPAP) use
Sleep Breath. 2018-06-26; 23(1): 217-226
Lire sur PubMed
Micoulaud-Franchi JA(1)(2), Coste O(3), Bioulac S(3)(4), Guichard K(3)(4), Monteyrol PJ(3), Ghorayeb I(3)(5), Weaver TE(6), Weibel S(7), Philip P(3)(4).
(1)Clinique du Sommei, Service d’Explorations Fonctionnelles du Système Nerveux, CHU de Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux, France.
(2)USR CNRS 3413 SANPSY, Université de Bordeaux, 33076, Bordeaux, France.
(3)Clinique du Sommei, Service d’Explorations Fonctionnelles du Système Nerveux,CHU de Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux, France.
(4)USR CNRS 3413 SANPSY, Université de Bordeaux, 33076, Bordeaux, France.
(5)CNRS, Institut de Neurosciences Cognitives et Intégratives d’Aquitaine, UMR 5287, Bordeaux, France.
(6)Department of Biobehavioral Health Science, Center for Narcolepsy, Sleep and Health, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA.
(7)Department of Psychiatry, University Hospital of Strasbourg, Strasbourg,France.
PURPOSE: The Self-Efficacy Measure for Sleep Apnea (SEMSA) is a 26-item
self-questionnaire composed of three factors: risk perception of obstructive
sleep apnea syndrome (OSAS), benefit of continuous positive airway pressure
(CPAP), and self-efficacy (the confidence to engage in CPAP use). It is used to
evaluate health beliefs about OSAS and CPAP in order to optimize CPAP use. The
purpose of this study was to design and validate a French version of the SEMSA.
METHODS: A forward-backward translation of the SEMSA was performed. Subjects with
OSAS treated by CPAP and followed by our sleep clinic were invited to complete
the questionnaire. The psychometric properties of the French SEMSA version were
analyzed in terms of its construct validity (with confirmatory factor analysis,
CFA), internal structural validity (Cronbach’s alpha coefficient), and external
validity (Pearson’s correlation between SEMSA score and duration of CPAP use).
RESULTS: Two hundred eighty-eight subjects filled in the questionnaire. The mean
age was 63.16 ± 12.73 years. The number of years since the beginning of CPAP
treatment was 6.58 ± 6.03 years. The mean CPAP use duration was
6.19 ± 2.03 h/night. CFA was unsatisfactory (RMSEA = 0.066 and CFI = 0.88). The
exploratory factor analysis revealed a fourth factor named « cardiovascular risk »
factor. Cronbach’s alpha coefficient was 0.886. The correlation between the
« self-efficacy » factor and the duration of CPAP use was significant (r = 0.26,
p ≤ 0.001).
CONCLUSIONS: The French version of the SEMSA is a psychometrically acceptable
self-report questionnaire for measuring health beliefs and behavior in French
patients with OSAS treated with CPAP. Such translation and validation should lead
to the adoption of validated psychosocial methods for improving CPAP use.